Kornimate/medical-research-clean huggingface dataset:
the effects of 15% dextrose solution on pain and range of motion in the hemiplegic shoulder

Conditions: Hemiplegic Shoulder Pain; Stroke

Summary: this study aims to investigate the effects of 15% dextrose solution on pain and range of motion in patients aged 40 to 75 years who have experienced a stroke and suffering from hemiplegic shoulder pain

this randomized, controlled, single-blinded clinical trial aims to evaluate the effects of 15% dextrose solution on pain and shoulder range of motion in patients with hemiplegic shoulder pain following a stroke. a total of 36 participants aged 40 to 75 years will be enrolled and randomly assigned into two groups of equal size. both groups will receive conventional exercise therapy. in addition, the intervention group will receive three sessions of 15% dextrose solution injections administered at two-week intervals, whereas the control group will receive three sessions of isotonic saline solution injections on the same schedule. assessments will be conducted at baseline, one month after the final injection, and three months after the final injection. the primary outcome measure is the change in pain intensity. secondary outcome measures include goniometric range of motion (rom) evaluation, visual analog scale (vas), barthel index for functional independence, and the shoulder section of the fugl-meyer upper extremity motor assessment scale(shoulder subsection). this study aims to determine whether 15% dextrose prolotherapy offers superior clinical outcomes in reducing pain and improving functional status compared to isotonic saline injection when combined with a standard exercise program.

Eligibility criteria:
inclusion criteria: patients aged between 40 and 75 years history of stroke brunnstrom stage 2 or higher in the upper extremity provided written informed consent and agreed to participate in the study exclusion criteria: history of any prior injection therapy to the shoulder region previous radiotherapy or surgery involving the shoulder pre-stroke shoulder pain history of shoulder surgery history of inflammatory joint disease presence of neuromuscular disorders full-thickness rotator cuff tear patients with aphasia or severe cognitive impairment presence of pectoral muscle spasticity active malignancy with acute inflammation at the treatment site known coagulation disorder with inr ≥ 4 presence of vascular conditions such as deep vein thrombosis, phlebitis, varicose veins, or arterial disease in the affected limb

Keywords: %15 prolotherapy %15 dextrose injection hemiplegic shoulder pain post-stroke rehabilitation fugl-meyer barthel ındex
pre-pectoral tissue expander and acellular dermal matrix for a two-stage muscle sparing breast reconstruction

Conditions: Breast Cancer

Summary: the aim of the research is to evaluate clinical outcomes of a two stage muscle sparing prepectoral breast reconstruction using tissue expander (te) entirely covered by an adm. the authors aim to report surgical indications, technical tips, clinical and histological outcomes with the final objective of delineate a decision-making algorithm for immediate prosthetic breast reconstruction.


Eligibility criteria:
inclusion criteria: * unilateral or bilateral mastectomy followed by two stage breast reconstruction with subcutaneous tissue expander and acellular dermal matrix (adm) * risk-reducing mastectomies followed by two stage breast reconstruction with subcutaneous tissue expander and adm exclusion criteria: * partial or total submuscular tissue expander placement, * tissue expander placement in conjunction with latissimus dorsi muscle flap or without adm, -delayed reconstructions * previous breast surgery
phase 1 sad and mad study of ngm282 in healthy adult participants

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine the safety and tolerability of ngm282, both single dose and multiple doses, in normal healthy adult participants.


Eligibility criteria:
inclusion criteria: * males or females, between 18 and 65 years of age, inclusive * bmi range is 20-35 kg/m2, inclusive for the sad module, and 25-35 kg/m2, inclusive for the mad module at screening; * in good health, determined by no clinically significant findings from medical history, physical exam, 12 lead ecg, clinical laboratory findings, and vital signs at screening and day -1 exclusion criteria: * significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gi, neurological, or psychiatric disorder (as determined by the pi) * history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
impact of dental anxiety coping module on children with dental anxiety

Conditions: Dental Anxiety

Summary: the aim of this study is to evaluate the impact of the dental anxiety coping module (dacm) in children with dental anxiety. the main questions to answer are: 1. will the dental anxiety coping module has any effect on dental anxiety in primary school children based on my-acdas and hrv-biofeedback? 2. is there any difference in dental anxiety between control and intervention group on baseline and post-test measured with my-acdas? 3. is there any difference in dental anxiety between control and intervention group on baseline, during and post-test measured with and hrv-biofeedback?

dental anxiety coping module (dacm) is a combination of dental tour and expressive art therapy. participants will be randomised into 2 groups, control group and intervention group (with dacm). control group will have dental procedure without any intervention. while the intervention group will start with dental tour where they will be shown around the dental clinic followed by expressive art therapy where they will have collage and finger painting done. after dacm, participants will continue with the same dental procedure as the control group.

Eligibility criteria:
inclusion criteria: * malaysian child, age 7 to 11 years old that understand basic malay and english language. * children that fulfil both my-acdas score 26 and above and hrv-biofeedback of very low coherence score (incoherence). * children with american society of anaesthesiologists (asa) i and asa ii classification. exclusion criteria: * children requiring emergency treatment such as pain, facial cellulitis, and trauma cases. * child with learning disabilities, hearing, or visual impairment, developmental or intellectual disability and cognitive impairment. * parents/guardians who refuse to allow their child to participate in this trial.
change in cognitive function in obese patients after bariatric surgery - an observational study

Conditions: Obesity; Bariatric Surgery

Summary: bariatric surgery provides a strong and long-term effect in reducing weight in obese subjects. studies showed that obesity and its comorbidities are associated with a lower cognitive performance. the aim of the researchers study is to examine the cognitive performance of the patients before and after bariatric surgery.


Eligibility criteria:
inclusion criteria: * bmi \> 40 * age: 18-60 exclusion criteria: * bmi \< 40 * age \ 60 * presence of cancer * presence of chronic inflammatory diseases * presence of addiction
determination of the accuracy of a non-invasive continuous blood pressure device

Conditions: Critically Ill

Summary: this protocol will test a new non-invasive device, the t-line, in continuously determining heart rate and blood pressure in operative and critically ill patients. the accuracy of the device will be compared to the standard radial artery catheter, as well as to the non-invasive blood pressure cuff. the t-line will also be compared to the right heart catheter determining cardiac output in at least 20 patients. hypothesis: the t-line device will determine blood pressure and heart rate as accurately as a standard radial arterial catheter and a blood pressure cuff in perioperative patients.


Eligibility criteria:
inclusion criteria: * age at least 18 years old * operative patients expected to require intensive care recovery at ohsu * planned or existing intra- and postoperative radial artery catheterization as part of routine care * palpable contralateral (to catheter) radial artery pulse * planned intraoperative right heart catheter placement as part of routine clinical care, in at least 20 subjects of total exclusion criteria: * no palpable radial artery pulse * anatomical abnormalities (skin grafts, cysts, cellulitis) or injuries (scarring, cuts, burns, bruising) at the sensor site * an intravenous line placed at the sensor application site or within the medial/lateral travel range of the sensor * an av shunt in the t-line arm * known sensitivity to pressure stimuli (dermatographism)

Keywords: blood pressure heart rate cardiac output critical care perioperative care
therapeutic drug monitoring of tyrosine kinase inhibitor in patients with chronic myeloid leukemia

Conditions: Tyrosine Kinase Inhibitor; Pharmacokinetics; Therapeutic Drug Monitoring

Summary: chronic myeloid leukemia (cml) consists of 3 clinical stages including chronic phase, accelerated phase and blast crisis. patients may only survive for few more days to weeks once the disease progresses to blast crisis, even though they might have been stable for several years in the chronic phase. the standard treatment, continuous use of tyrosine kinase inhibitors (tkis), improves long-term survival, and even may help patients achieve complete remission. four tkis are reimbursed by national health insurance in taiwan. among them, imatinib, nilotinib as well as dasatinib, and ponatinib are the first, second and third generations of tkis, respectively. many factors influence the disease control of cml, such as tki type, genetic mutation and medication adherence. only 69% of patients followed their physicians' recommendations in a local survey. the medication adherence of tkis was compromised based on several clinical studies domestically and worldwide due to the slow progression in the chronic phase. patients might hold or decrease the dose of tkis on their own when they suffer side effects. furthermore, the significant intra-subject variations of tki plasma concentration and drug-drug and drug-food interactions which alter the metabolism of tkis may lessen therapeutic effect and patient safety. therefore, this study aims to develop and validate analytic methods of imatinib, dasatinib, nilotinib and ponatinib plasma concentrations. the investigators plan to build the pharmacokinetic models of these 4 tkis and analyze the impacts of meals, adherence, hepatic enzyme inhibitors and inducers, antacids, proton pump inhibitors and h2 blockers, etc. adverse drug reactions and treatment outcomes will be evaluated to determine the availability and feasibility of therapeutic drug monitoring of tkis as part of routine service in pharmacist-led clinics.


Eligibility criteria:
inclusion criteria: 1. adult patients (≥ 20 year-old) 2. patients who meet the above criteria and have already initiated or are going to receive imatinib, dasatinib, nilotinib, or ponatinib treatment at national taiwan university hospital/national taiwan university cancer center from september 2022 to december 2025 exclusion criteria: 1. patients who are unable to cooperate with blood drawing 2. patients who have not submit the informed consent

Keywords: tyrosine kinase inhibitor pharmacokinetics therapeutic drug monitoring
a non-interventional pilot study to explore the role of gut flora in bipolar disorder

Conditions: Bipolar Disorder; Bipolar I Disorder; Bipolar II Disorder; Bipolar Type I Disorder; Bipolar Disorder Mild; Bipolar Disorder Moderate; Bipolar Disorder Severe

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to bipolar disorder

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. may be signed by parent or legal guardian in the case of minor or adult unable to provide consent 2. male or female of all ages. 3. greater than seven endorsements on the bipolar disorder questionnaire. exclusion criteria: 1. refusal to sign informed consent form 2. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 3. postoperative stoma, ostomy, or ileoanal pouch 4. participation in any experimental drug protocol within the past 12 weeks 5. treatment with total parenteral nutrition
persona mc vs ps rct with rosa

Conditions: Total Knee Arthroplasty

Summary: a randomized, controlled study comparing two total knee implant devices, persona medial congruent (mc) vs posterior stabilized (ps). these surgeries will be performed using the rosa robotic system. patients will be followed up to 5 years.


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age 2. patients scheduled an elective primary tka for a diagnosis of osteoarthritis or inflammatory arthritis using the rosa knee system. 3. patient is willing to cooperate and follow study protocol and visit schedule 4. subject has access to a device is capable of pairing to the apple watch, supporting application updates and is compatible with the mymobility app. exclusion criteria: 1. patient is pregnant 2. patient is unable to provide written consent 3. revision tka 4. history of prior infection in the affected knee 5. history of prior open surgery with significant hardware in place on the affected knee (i.e. prior distal femur or proximal tibia fracture or osteotomy) 6. preoperative diagnosis of post-traumatic arthritis, avascular necrosis, or fracture
effects of ergocalciferol on erythropoetin stimulating agent dose

Conditions: Chronic Kidney Disease Stages 3-5

Summary: hypothesis: the supplementation of ergocalciferol (vitamin d2) to those with vitamin d deficiency in the chronic kidney disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.


Eligibility criteria:
inclusion criteria: * chronic kidney disease * age: \>18yo * stable hemoglobin (hgb) for 1 month on stable dose of erythropoietin for 1 month (defined as erythropoietin dose within 15% of previous months erythropoietin dose) * unchanged maintenance oral or intravenous (iv) iron therapy for 1 month * serum 25-hydroxy vitamin d levels \< 30 ng/ml * history of 25-hydroxy vitamin d levels \< 30 ng/ml currently on ergocalciferol replacement exclusion criteria: * on hemodialysis * chronic kidney disease 5 * hypercalcemic (calcium level \> 11mg/dl) * pregnant female * iron deficient (iron saturation \< 20%, ferritin \< 100ng/ml) * presence of active malignancy * presence of active infections * presence of active inflammatory properties * presence of blood dyscrasias * active bleeding or bleeding within the past 3 months (other than menses) * b12 deficiency * folate deficiency * blood transfusion during participation * parathyroid levels exceeding the expected levels allowed for the stage of a subjects chronic kidney disease (target parathyroid in: chronic kidney disease 3 35-70 pg/ml, chronic kidney disease 4 70-110 pg/ml)
assessment of the initial efficacy and safety of brm424 ophthalmic solutions in patients with neurotrophic keratitis

Conditions: Neurotrophic Keratitis

Summary: the objective of this study is to obtain initial efficacy of brm424 in patients with stage 2 and stage 3 nk and evaluate safety and tolerability.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age; * provide written informed consent; * patients with nk stage 2 (ped) or stage 3 (corneal ulcer); exclusion criteria: * any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to nk; * anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days treatment period in the eye(s) with nk; * be a woman of childbearing potential who is not using an acceptable means of birth control;
the impact of a virtual reality environment on phantom limb pain

Conditions: Phantom Limb Syndrome With Pain

Summary: phantom limb pain occurs in the majority of people who lose a limb. it significantly affects quality of life and is hard to manage. recent evidence suggests that mirror therapy and similar techniques that create a visual representation of the missing limb under the control of the patient may reduce phantom limb pain. the investigators previously explored the use of a virtual reality environment for this purpose with people with upper limb loss but found that using it within the clinical setting limited its potential efficacy. phantom limb pain is highly variable and assessing the effects of the activity during a hospital appointment when the phantom pain may not be present, or may not be problematic, made it difficult to judge the effects adequately. this study involves training the patient in the clinic to use a portable, self-contained virtual reality system which they will then use at home, unsupervised, for 2 months. the aim is to discover whether phantom limb pain intensity decreases by performing an activity in a virtual reality environment in which a visual representation of the missing limb is controlled by the patient. participants will be directed to use the system every day, and whenever their phantom limb pain is present and problematic.


Eligibility criteria:
inclusion criteria: * over 18 years of age. * unilateral upper limb amputee (transradial and transhumeral). * amputation occurred at least 6 months ago. * stump has fully healed and has no ulcerations present. exclusion criteria: * amputation of digit(s) only. * the presence of a wound, ulcer or broken skin on the residual limb. * the presence of a psychiatric disorder. * have pre-existing binocular vision abnormalities. * a history of seizures or epilepsy. * a pacemaker or other implanted medical device that could be affected by magnets or components that emit radio waves. * lacking the capacity to understand the instructions on how to use the virtual reality equipment. * lacking the capacity to consent. * unable to comply with the requirements of the study.

Keywords: phantom limb pain virtual reality virtual environment
prospective multicenter study on clinical application of sonazoid in breast tumor

Conditions: Ultrasound

Summary: sonazoid as a new generation of ultrasound contrast agent.this study based on the features of sonazoid specific angiography and high mechanical index,the role of sonazoid in the differential diagnosis of breast benign and malignant tumors was explored.

this trial is a prospective, multi-center study.with pathology as the gold standard, based on quantitative and qualitative analysis, sonazoid-ceus was compared with mri to explore the diagnostic efficacy (accuracy, sensitivity and specificity) of sonazoid-ceus for breast tumor in different pathological types. investigators will also record the parameter information of imaging examination, pathological type of pathological examination and immunohistochemical index.contrast-enhanced ultrasound includes lesion location, initial peak tumor volume, 1-minute tumor volume, 2-minute tumor volume, and 5-minute tumor volume, as well as the time for contrast enhancement, contrast agent clearance, and contrast agent clearance.whether there is no enhancement area in the lesion after contrast enhancement, shape after contrast enhancement, edge after contrast enhancement, order of enhancement, uniformity of enhancement, intensity enhancement, pattern of enhancement, clear boundary after contrast enhancement, aspect ratio after contrast enhancement, etc.the magnetic field strength of the equipment is planned to be recorded in the enhanced mri information, the name of the mri contrast agent, the lesion location, the size of the lesion, and the scanning performance are enhanced (lump-like enhancement, non-lump-like enhancement, point-like enhancement), time-signal intensity enhancement curve, dwi signal, adc value, etc.

Eligibility criteria:
inclusion criteria: 1. conventional ultrasonography suggested definite lesions in the breast; 2. in addition to conventional ultrasound, there is also enhanced mri examination; 3. there are no contraindications for puncture biopsy, and pathological examination (cytology, histology) is planned to examine the patients with target lesions 4. patients volunteered to participate in the study and signed informed consent.- exclusion criteria: 1. those who are known to be allergic to ultrasound contrast agents; 2. the subject has a history of allergy to eggs or egg products (i.e. skin rash, dyspnea, swelling of the mouth or throat, hypotension or shock, etc.) 3. arteriovenous (left and right) shunt patients in the heart and lungs 4. patients with serious heart disease or serious lung disease 5. patients who are pregnant, possibly pregnant or lactating 6. patients who cannot receive contrast agent mri 7. in addition, the investigator or the patient that the investigator considers not suitable to participate in this study

Keywords: breast
trial comparing single versus double incision to repair distal bicep tendon ruptures

Conditions: Distal Bicep Tendon Rupture

Summary: the purpose of this study to to determine whether a single incision technique or a double incision technique is more effective in the surgical treatment of distal bicep tendon ruptures. patients will be randomized to one of the two techniques upon consenting to the study. prior to surgery patients will have their elbow flexion, extension, pronation, and supination strength measured. elbow range of motion will also be measured in each of these four movements. a number of subjective questionnaires will also be administered to the patient prior to surgery. the identical objective tests and subjective questionnaires will be completed by the patient at intervals of three months, six months, one year, and two years following their surgery. additional information from patients clinical visits may also be collected throughout the study.


Eligibility criteria:
inclusion criteria: * complete rupture of the distal bicep tendon * acute bicep tendon rupture (\< 10 days since rupture) * 18 years of age and older exclusion criteria: * partial rupture of the distal bicep tendon * chronic bicep tendon ruptures (\>10 days since rupture) * under 18 years of age

Keywords: bicep tendon distal ruptures randomized surgery
analgesic effect of paracetamol in patients with femur fracture: is intravenous better than oral?

Conditions: Femur Fracture

Summary: the purpose of this study is to monitor severe pain for femur fracture after treatment with paracetamol iv or or.

the investigators enrolled 170 consecutive patients with femur fracture and severe pain. the patients received an initial analgesic treatment with paracetamol orally (or) or intravenously (iv). the primary outcome was the reduction of pain of 1 point at visual analogue scale for pain (vas) after the 1 st hour of treatment (t1). secondary endpoints included the reduction of pain of at least 2 points on the vas scale at the 4 th hour (t4), the need of rescue therapy and the number of adverse events.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients admitted to the ed of fondazione policlinico universitario a. gemelli, irccs, rome * femur fracture * patients who signed the informed consent * able to take analgesic therapy both orally (or) and intravenously (iv) * able to define pain by vas exclusion criteria: * age \<18 years * allergy to paracetamol * unable to take analgesic therapy both orally (or) and intravenously (iv) * unable to define pain by vas

Keywords: femur fracture pain paracetamol emergency department